One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

In two Phase III trials the chemo potentiating effect of PARP inhibitors on other drugs is being investigated. The recent observation that HR can be downregulated by hyperthermia treatment holds ...

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...

Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of ...

We applied the principle of synthetic lethality to discover a novel strategy for cancer treatment for patients with BRCA1 or BRCA2 gene mutations. We demonstrated that drugs called PARP inhibitors ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a cell’s ability to repair DNA damage. Four PARPis are currently approved for use in the ...

this time in first-line treatment of advanced ovarian cancer. Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease ...

As well as the above there are specific entry conditions for each treatment group. Speak to your doctor or research nurse if you ... The team can tell you more about this. For those who are having a ...

The digital meeting will capitalize on the therapeutic application of PARP inhibitors by finding optimal treatment combinations and expanding its use in cancer indications, as well as exploring ...